Literature DB >> 12415437

Oral contraceptives and bone mineral density in white and black women in CARDIA. Coronary Risk Development in Young Adults.

K L Cobb1, J L Kelsey, S Sidney, B Ettinger, C E Lewis.   

Abstract

To examine whether exposure to oral contraceptives (OCs) is associated with bone mineral density (BMD) in young women, we studied, cross-sectionally and longitudinally, 216 white and 260 black women enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Spine, hip and whole body BMDs were measured by dual-energy X-ray absorptiometry (DXA) when the women were aged 25-37 years, and whole body BMD was remeasured in 369 of the women 3 years later. A comprehensive history of OC use, including dose of ethinyl estradiol (estrogen) and duration of use, was determined from an interviewer-administered questionnaire. After adjustment for other relevant variables, we found that cumulative estrogen from OCs (mg) explained 4.0% of the variation in spine BMD ( p = 0.024) among white women, but did not explain any of the variance in BMD in black women. Cumulative OC estrogen was associated with a decreased risk for low bone density (lowest quartile) at the spine, hip and whole body in white women. The odds ratios (95% CIs) comparing women in the highest quartile of cumulative OC estrogen with those in the lowest quartile were, at the spine: 0.08 (0.02, 0.46); at the hip: 0.23 (0.06, 0.87); and at the whole body: 0.37 (0.11, 1.26). OC exposure was not related to low bone density in black women. OCs did not predict longitudinal changes in whole body BMD in either race. These results suggest that exposure to the estrogen from OCs during the premenopausal years may have a small beneficial effect on the skeleton in white women. Benefit is proportional to the cumulative estrogen exposure, suggesting that previous cross-sectional studies that considered OC use as a dichotomous variable may have lacked the power to detect an association.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12415437     DOI: 10.1007/s001980200123

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  11 in total

Review 1.  Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review.

Authors:  S L Liu; C M Lebrun
Journal:  Br J Sports Med       Date:  2006-01       Impact factor: 13.800

2.  Determinants of skeletal loss and recovery in anorexia nervosa.

Authors:  Karen K Miller; Ellen E Lee; Elizabeth A Lawson; Madhusmita Misra; Jennifer Minihan; Steven K Grinspoon; Suzanne Gleysteen; Diane Mickley; David Herzog; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2006-05-30       Impact factor: 5.958

3.  Fat mass modifies the association of fat-free mass with symptom-limited treadmill duration in the Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  Na Zhu; David R Jacobs; Stephen Sidney; Barbara Sternfeld; Mercedes Carnethon; Cora E Lewis; Christina M Shay; Akshay Sood; Claude Bouchard
Journal:  Am J Clin Nutr       Date:  2011-06-08       Impact factor: 7.045

Review 4.  Update on hormonal contraception and bone density.

Authors:  Michelle M Isley; Andrew M Kaunitz
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

5.  Oral contraceptive use and bone mass in women aged 26-36 years.

Authors:  S Wei; G Jones; R Thomson; T Dwyer; A Venn
Journal:  Osteoporos Int       Date:  2010-02-27       Impact factor: 4.507

6.  Four decades of research on hormonal contraception.

Authors:  Diana B Petitti; Stephen Sidney
Journal:  Perm J       Date:  2005

Review 7.  Hormonal contraception and HIV-positive women: metabolic concerns and management strategies.

Authors:  Julie Womack; Susan Richman; Phyllis C Tien; Margaret Grey; Ann Williams
Journal:  J Midwifery Womens Health       Date:  2008 Jul-Aug       Impact factor: 2.388

Review 8.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 9.  A biomechanical sorting of clinical risk factors affecting osteoporotic hip fracture.

Authors:  Y Luo
Journal:  Osteoporos Int       Date:  2015-09-11       Impact factor: 4.507

Review 10.  Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update.

Authors:  Emily S Mohn; Hua J Kern; Edward Saltzman; Susan H Mitmesser; Diane L McKay
Journal:  Pharmaceutics       Date:  2018-03-20       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.